CryositeASX:CTE +8.49%51 Net Margin % is 13.76% as of Dec. 2025, which is 52% above its 10-year median of 9.06. GuruFocus rates ASX:CTE with a GF Score™ of 51/100 and a GF Value™ of A$0.94 (Modestly Overvalued). Among 204 Medical Diagnostics & Research companies, Cryosite ranks better than 84.8% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Cryosite's Net Income for the
six
months ended in Dec. 2025 was A$1.14 Mil. Cryosite's Revenue for the
six
months ended in Dec. 2025 was A$8.27 Mil. Therefore, Cryosite's net margin for the quarter that ended in Dec. 2025 was 13.76%.
The historical rank and industry rank for Cryosite's Net Margin % or its related term are showing as below:
ASX:CTE'
s Net Margin % Range Over the Past 10 Years
Min: -21.15 Med: 9.06 Max: 16.59
Current: 13.87
ASX:CTE's Net Margin % is ranked better than 84.8% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs ASX:CTE: 13.87
Cryosite (ASX:CTE) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cryosite Net Margin % Related Terms
Cryosite Net Margin % Historical Data
* Premium members only.
The historical data trend for Cryosite's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CTE vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Cryosite's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryosite Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cryosite's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryosite (ASX:CTE) has a Net Margin % of 13.76% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Cryosite and its competitors. This is 52% above median its historical median of 9.06. According to the industry distribution chart, Cryosite ranks #31 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 15.2%.
Is Cryosite's Net Margin % too high?
Cryosite's current Net Margin % of 13.76% is 52% above median its 10-year median of 9.06. Based on the distribution chart, Cryosite ranks #31 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cryosite has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #31 out of 204 companies for Net Margin %. This places Cryosite in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cryosite and its competitors. Cryosite's current Net Margin % is 13.76%, which is 52% above median its own 10-year median of 9.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.15 — trading 22.3% above its estimated fair value. The current Net Margin % is 13.76%, which is 52% above median its 10-year median of 9.06. Cryosite's overall GF Score™ is 51/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Net Margin % is 13.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.15 is trading 22.3% above its estimated GF Value™ of A$0.94.
GuruFocus considers Cryosite to be Modestly Overvalued.
Key valuation signals for ASX:CTE:
Net Margin %: 13.76% (52% above median its 10-year median of 9.06)
GF Value™: A$0.94 vs. price of A$1.15 (22.3% above fair value)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score
Get the complete analysis for ASX:CTE
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 
